Insider Shareholders with Direct Ownership of Bei Gene, Ltd. (BGNE)
This section provides a comprehensive overview of the insiders with direct ownership of Bei Gene, Ltd. (BGNE). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
BeiGene, Ltd. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Amgen Inc
> 10% Shareholder |
30,385,569 | 0 | 18,943,802 $3.68 Billion | 12 |
Sep 10, 2021
Added 0.87%
|
|
Xiaodong Wang
Director |
432,845 | 2,124,985 | 5,266,973 $1.02 Billion | 22 |
Aug 12, 2024
Reduced 5.41%
|
|
Donald W. Glazer
Director |
53,755 | 832,969 | 2,718,464 $528 Million | 10 |
Jun 05, 2024
Added 0.6%
|
|
Aaron Rosenberg
Chief Financial Officer |
118,547 | 0 | 118,547 $23 Million | 1 |
Aug 09, 2024
Added 50.0%
|
|
Anthony C Hooper
Director |
53,755 | 0 | 53,755 $10.4 Million | 4 |
Jun 05, 2024
Added 23.31%
|
|
Thomas Malley
Director |
37,414 | 0 | 46,696 $9.07 Million | 3 |
Jun 15, 2023
Added 21.67%
|
|
Corazon (Corsee) D. Sanders
Director |
53,755 | 578 | 46,241 $8.98 Million | 5 |
Jun 05, 2024
Added 26.11%
|
|
Qingqing Yi
Director |
53,755 | 7,800 | 45,955 $8.93 Million | 5 |
Jun 05, 2024
Added 26.23%
|
|
Margaret Dugan
Director |
45,955 | 0 | 45,955 $8.93 Million | 3 |
Jun 05, 2024
Added 26.23%
|
|
Alessandro Riva
Director |
45,955 | 0 | 45,955 $8.93 Million | 3 |
Jun 05, 2024
Added 26.23%
|
|
Olivier Brandicourt
Director |
16,341 | 0 | 16,341 $3.17 Million | 1 |
Jun 05, 2024
Added 50.0%
|
| 127,454 | 27,032 | 10,418 $2.02 Million | 3 |
Oct 13, 2020
Reduced 56.47%
|
|
|
Shalini Sharp
Director |
8,151 | 0 | 8,151 $1.58 Million | 1 |
Sep 30, 2024
Added 50.0%
|
|
Timothy Yung Cheng Chen
Director |
13,800 | 6,000 | 7,800 $1.52 Million | 5 |
Jun 16, 2021
Added 50.0%
|
|
Jingshyh S Su
Director |
7,800 | 0 | 7,800 $1.52 Million | 1 |
Jun 16, 2021
Added 50.0%
|
|
Julia Aijun Wang
Chief Financial Officer |
410,137 | 5,293 | 0 $0 | 15 |
Jul 01, 2024
Reduced 100.0%
|
|
John Oyler
Chief Executive Officer |
1,326,364 | 3,526,980 | 0 $0 | 31 |
Jun 24, 2024
Reduced 100.0%
|
|
Lai Wang
Global Head of R&D |
1,715,389 | 68,687 | 0 $0 | 19 |
Jun 24, 2024
Reduced 100.0%
|
|
Xiaobin Wu
President, COO & GM China |
719,732 | 75,980 | 0 $0 | 25 |
Sep 19, 2024
Reduced 100.0%
|
|
Jane Huang
CMO, Hematology |
110,822 | 63,574 | 0 $0 | 43 |
Dec 14, 2021
Reduced 100.0%
|
|
Titus B. Ball
Principal Accounting Officer |
24,427 | 137 | 0 $0 | 2 |
Sep 03, 2024
Reduced 100.0%
|
|
Howard Liang
CFO & Chief Strategy Officer |
1,525,200 | 121,482 | 0 $0 | 11 |
Jun 28, 2021
Reduced 100.0%
|
|
Chan Henry Lee
SVP, General Counsel |
163,670 | 3,266 | 0 $0 | 6 |
Sep 30, 2024
Reduced 100.0%
|